On October 16, 2025, MIRA Pharmaceuticals, Inc. announced that oral Mira‑55 outperformed injected morphine in a study, fully normalizing pain and significantly reducing inflammation. The data, presented in a press release from the company’s Miami headquarters, directly supports the planned Investigational New Drug (IND) filing for chronic inflammatory pain.
The study demonstrated that oral Mira‑55 achieved complete pain normalization and a marked anti‑inflammatory effect, outperforming the standard opioid treatment. These findings provide robust preclinical evidence that the oral formulation can deliver superior efficacy while avoiding the risks associated with morphine.
The results reinforce MIRA’s position in the $70 billion non‑opioid pain market, underscoring the commercial potential of Mira‑55 as a non‑opioid alternative for patients with chronic inflammatory conditions.
By confirming the drug’s efficacy and safety profile, the data strengthens the company’s IND filing prospects and positions MIRA for a potentially faster regulatory review, which could accelerate the path to market entry and broaden its therapeutic portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.